A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

Inclusion Criteria: * Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney. * Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure. Exclusion Criteria: * Patient has received or is receiving an organ transplant other than kidney * Patient has received a kidney transplant from a cadaveric donor \>= 60 years of age.